Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Believing that the science underlying beta blockers had other uses, he left ICI for the greater freedom offered by Smith Kline. Black’s hopes were realised....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...“Advil [ibuprofen] switched in 1984, and still brings in $300-400m a year” for Pfizer. Like several other companies, Pfizer has set up its own consumer health division to handle switches....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Mr Kindler also placed some big new “bets”: investing in regenerative medicine and high value “orphan drugs”; and agreeing risk- and revenue-sharing deals with Bristol-Myers Squibb and GlaxoSmith-Kline....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...When the chief executive of GlaxoSmithKline presented his company’s most recent financial results last month, he gave a sense of how the UK’s biggest drugmaker – and the industry more generally – is responding...
...But it is smaller than rivals such as Pfizer, Sanofi-Aventis and Novartis and Mr Hussain saw the need to push much further....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...GSK this year went much further, announcing a deal with Pfizer to pool all of their existing and experimental drugs for HIV....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Merck’s and GlaxoSmithKline’s recent HPV vaccines offer the prospect of preventing a high proportion of cervical cancers. These drugs have also proved expensive....
...AstraZeneca and GlaxoSmith-Kline fell 2.1 per cent to £30.10 and 1.9 per cent to £13.60 respectively....
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
...Pharmaceutical companies such as Eli Lilly, GlaxoSmith-Kline, Merck and Pfizer gave a bigger proportion of in-kind donations, consisting largely of medicine and supplies....
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
...Even Pfizer, the world's largest drug company, in which I had sporadically held shares, seemed to be unable to turn its 20 per cent annual growth in earnings per share into a higher share price....
International Edition